Abstract
To investigate the performance of high-order radiomics features and models based on T2-weighted fluid-attenuated inversion recovery (T2 FLAIR) in predicting the immunohistochemical biomarkers of glioma, in order to execute a non-invasive, more precise and personalized glioma disease management. 51 pathologically confirmed gliomas patients committed in our hospital from March 2015 to June 2018 were retrospective analysis, and Ki-67, vimentin, S-100 and CD34 immunohistochemical data were collected. The volumes of interest (VOIs) were manually sketched and the radiomics features were extracted. Feature reduction was performed by ANOVA+ Mann-Whiney, spearman correlation analysis, least absolute shrinkage and selection operator (LASSO) and Gradient descent algorithm (GBDT). SMOTE technique was used to solve the data bias between two groups. Comprehensive binary logistic regression models were established. Area under the ROC curves (AUC), sensitivity, specificity and accuracy were used to evaluate the predict performance of models. Models reliability were decided according to the standard net benefit of the decision curves. Four clusters of significant features were screened out and four predicting models were constructed. AUC of Ki-67, S-100, vimentin and CD34 models were 0.713, 0.923, 0.854 and 0.745, respectively. The sensitivities were 0.692, 0.893, 0.875 and 0.556, respectively. The specificities were: 0.667, 0.905, 0.722, and 0.875, with accuracy of 0.660, 0.898, 0.738, and 0.667, respectively. According to the decision curves, the Ki-67, S-100 and vimentin models had reference values. The radiomics features based on T2 FLAIR can potentially predict the Ki-67, S-100, vimentin and CD34 expression. Radiomics model were expected to be a computer-intelligent, non-invasive, accurate and personalized management method for gliomas.
Highlights
Glioma is the most common neuroepithelial tumor of the cerebral nervous system
High-order radiomics features based on T2 FLAIR MRI predict multiple glioma immunohistochemical features
High-order radiomics features based on T2 FLAIR MRI predict multiple glioma immunohistochemical features appearing more and more radiomics-based tools for studying gliomas
Summary
Glioma is the most common neuroepithelial tumor of the cerebral nervous system. Accurate grading of glioma is meaningful for clinics, significantly different prognosis exists among individuals who were classified as the same grade [1,2,3]. Great progress was obtained in the molecular pathology of neuro-tumors and a series of molecular markers have been found to be helpful in the clinical differential diagnosis and prognosis predicting of gliomas, among which Ki-67, vimentin, CD34 and S-100 are four vital biological behavior biomarkers [11,12,13,14,15]. CD34 expression is candidate as a prognostic biomarker in glioblastoma to identify survival and could be predictive for efficacy of bevacizumab [20] These diagnosis guidelines or studies indicate that fully consider the molecular pathology may greatly help confirm gliomas sub-type and prognostic prediction. The pathological histology of glioma after surgical resection or biopsy is the golden standard for gliomas grading and immunohistochemical typing It has some inadequacies such as invasiveness, untimely sampling, time-consuming, sampling errors and different histological interpretations [21]. It is necessary to find an effective and non-invasive approach to classify different glioma immunohistochemical subtypes
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.